

# MR-Linac

## Technical Details and Physics Developments



**Brian M. Keller, PhD**

**January 24, 2019**

# *Objectives*


- To address some of the dosimetric differences of the MR-Linac
- To outline some of the current physics related research and development

# Validation of Monaco – With B-field




Ahmad S, Sarfehnia A, Paudel M, Kim A, Hissoiny S, Sahgal A and Keller B. Evaluation of a commercial MRI linac based Monte Carlo dose calculation algorithm with Geant4. *Med Phys* 43(2), 894 - 907, 2016.

# Irradiating in a Magnetic Field



*Ahmad S, Sarfehnia A, Kim A, Wronski M, Sahgal A and Keller B. Backscatter dose effects for high atomic number materials being irradiated in the presence of a magnetic field: A Monte Carlo study for the MRI Linac. Med Phys 43 (8), 4665-4673, 2016.*




# ERE Effects: Dose Difference Maps



Chen et al. Dose effects of 1.5 T transverse magnetic field on tissue interfaces in MRI-guided radiotherapy. *Med Phys* 43(8), 4797, 2016

# Magnetic field dose effects on different radiation beam geometries for hypofractionated partial breast irradiation

Anthony Kim<sup>1,2</sup> | Stephanie Lim-Reinders<sup>1</sup> | Claire McCann<sup>1,2</sup> | Syed Bilal Ahmad<sup>1</sup> |  
 Arjun Sahgal<sup>2,3</sup> | Justin Lee<sup>2,3</sup> | Brian M. Keller<sup>1,2</sup> *J Appl Clin Med Phys* 2017; 18:6: 62–70




# The development of a 4D treatment planning methodology to simulate the tracking of central lung tumors in an MRI-linac

Shahad M. Al-Ward<sup>1</sup> | Anthony Kim<sup>1,2</sup> | Claire McCann<sup>1,2</sup> | Mark Ruschin<sup>1,2</sup> |

Patrick Cheung<sup>1,2</sup> | Arjun Sahgal<sup>1,2</sup> | Brian M. Keller<sup>1,2</sup>


*J Appl Clin Med Phys* 2018; 19:1: 145–155



*On average, irradiated volume reduced by ~ 30%*


*OAR Sparing resulted from*

- Tumours with larger motions
- Close proximity of OAR to tumour




# Simulated Tumour Tracking In a Magnetic Field : Liver, Pancreas, Kidney


Liver



Pancreas



Kidney








PAPER

# The radiobiological impact of motion tracking of liver, pancreas and kidney SBRT tumors in a MR-linac

Shahad Al-Ward<sup>1</sup>, Matt Wronski<sup>1,2</sup>, Syed Bilal Ahmad<sup>1,2</sup>, Sten Myrehaug<sup>1,2</sup>, William Chu<sup>1,2</sup>, Arjun Sahgal<sup>1,2</sup> and Brian M Keller<sup>1,2,3</sup> *Phys. Med. Biol.* 63 (2018) 215022 (11pp)




# MR-linac Designed Water Tank



Harry Easton and Machine Shop

# Daily Morning Output Measurements Device



Harry Easton and Machine Shop



# Differences in NTCP values for ITV vs MLC Tracking




Figure 1. Plots of NTCP as a function of EUD for various organs at risk (OARs), where each OAR has its associated  $m$  and  $D_{50}$  values as listed in table 2.

# The Radiobiological Impact of Motion Tracking of Liver, Pancreas and Kidney SBRT Tumors in a MR-linac

Treatment site: Liver								
Patient 1	Tumor motion= 0.96 cm		Patient 2	Tumor motion= 2.57 cm		Patient 3	Tumor motion= 1.00 cm	
OAR	<i>a</i>	% NTCP difference	OAR	<i>a</i>	% NTCP difference	OAR	<i>a</i>	% NTCP difference
Liver-ITV	3	5	Liver-ITV	0.5	5	Liver-ITV	3	1
Right Kidney	0.5	2	Liver-ITV	1	17	Duodenum	4	13
Right Kidney	1	35	Liver-ITV	3	51	Duodenum	8	24
Duodenum	4	12	Right Kidney	3	79	Duodenum	15	25
Duodenum	8	15	Skin	8	1	Bowels	4	19
Duodenum	15	10	Skin	15	1	Bowels	8	44
Bowels	15	17				Bowels	15	9
Treatment site: Pancreas								
Patient 4	Tumor motion= 0.80 cm		Patient 5	Tumor motion= 1.05 cm		Patient 6	Tumor motion= 0.81 cm	
OAR	<i>a</i>	% NTCP difference	OAR	<i>a</i>	% NTCP difference	OAR	<i>a</i>	% NTCP difference
Duodenum	4	17	Duodenum	4	10	Duodenum	4	6
Duodenum	8	7	Duodenum	8	7	Duodenum	8	1
Duodenum	15	2	Duodenum	15	5	Duodenum	15	-2
Small bowel	8	4						
Small bowel	15	67						
Large bowel	8	10						
Large bowel	15	69						
Stomach	8	-5						
Stomach	15	-16						
Treatment site: Kidney								
Patient 7	Tumor motion= 1.21 cm		Patient 8	Tumor motion= 0.78 cm		Patient 9	Tumor motion= 1.17 cm	
OAR	<i>a</i>	% NTCP difference	OAR	<i>a</i>	% NTCP difference	OAR	<i>a</i>	% NTCP difference
Duodenum	4	2	Duodenum	15	1	Duodenum	4	4
Duodenum	8	3	kidney-ITV	0.5	77	Duodenum	8	4
Duodenum	15	3	kidney-ITV	1	48	Duodenum	15	5
kidney-ITV	0.5	15	kidney-ITV	3	1	kidney-ITV	0.5	69
			Large Bowel	8	4	kidney-ITV	1	56
			Large Bowel	15	18			